Can you provide the last earnings date for CERIDIAN HCM HOLDING INC?
CERIDIAN HCM HOLDING INC (CDAY) last reported earnings on 2/7/2024.
NYSE:CDAY • US15677J1088
Past quarterly earnings results for CERIDIAN HCM HOLDING INC (CDAY), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2023 | 0.37 | 0.30 | 22.60% | 85.00% | 377.5M | 377.15M | 0.09% | 19.61% |
| Q2 2023 | 0.32 | 0.30 | 7.19% | 52.38% | 365.9M | 365.57M | 0.09% | 21.48% |
| Q1 2023 | 0.31 | 0.32 | -3.23% | 138.46% | 370.6M | 368.3M | 0.62% | 26.36% |
| Q4 2022 | 0.23 | 0.12 | 87.42% | 283.33% | 336.1M | 331.65M | 1.34% | 19.14% |
| Q3 2022 | 0.20 | 0.13 | 58.68% | 300.00% | 315.6M | 311.67M | 1.26% | 22.71% |
| Q2 2022 | 0.21 | 0.10 | 105.88% | 250.00% | 301.2M | 300.44M | 0.25% | 20.29% |
| Q1 2022 | 0.13 | 0.08 | 58.05% | 44.44% | 293.3M | 295.21M | -0.65% | 25.07% |
| Q4 2021 | 0.06 | 0.03 | 85.62% | -33.33% | 282.1M | 280.59M | 0.54% | 26.62% |
| Q3 2021 | 0.05 | 0.05 | 8.52% | -58.33% | 257.2M | 258.61M | -0.55% | 25.83% |
| Q2 2021 | 0.06 | 0.04 | 55.54% | -53.85% | 250.4M | 241.78M | 3.57% | 30.01% |
| Q1 2021 | 0.09 | 0.09 | 0.10% | -40.00% | 234.5M | 227.1M | 3.26% | 5.30% |
| Q4 2020 | 0.09 | 0.08 | 18.55% | - | 222.8M | 221.83M | 0.44% | - |
| Q3 2020 | 0.12 | 0.05 | 125.64% | - | 204.4M | 204.4M | - | - |
| Q2 2020 | 0.13 | 0.06 | 110.32% | - | 192.6M | 197.49M | -2.48% | - |
| Q1 2020 | 0.15 | 0.11 | 30.72% | - | 222.7M | 222.52M | 0.08% | - |
Notes
CERIDIAN HCM HOLDING INC (CDAY) last reported earnings on 2/7/2024.
CERIDIAN HCM HOLDING INC (CDAY) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, CERIDIAN HCM HOLDING INC (CDAY) has beaten EPS estimates in 3 out of 4 releases.